http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 21:24:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+ILJIN+SNT+Co.%2C+Ltd./26983317.html si-local-file:///var/storage/secattach/20260826/26983317.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+ILJIN+SNT+Co.%2C+Ltd./26983317.html Wed, 26 Aug 2026 21:24:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+ILJIN+SNT+Co.%2C+Ltd./26983317.html si-local-file:///var/storage/secattach/20260826/26983317.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+ILJIN+SNT+Co.%2C+Ltd./26983317.html Wed, 26 Aug 2026 21:24:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+21++Filed+by%3A+Robertson+Stephen+P./26976146.html si-local-file:///var/storage/secattach/20260825/26976146.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+21++Filed+by%3A+Robertson+Stephen+P./26976146.html Tue, 25 Aug 2026 21:29:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+21++Filed+by%3A+Robertson+Stephen+P./26976146.html si-local-file:///var/storage/secattach/20260825/26976146.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+21++Filed+by%3A+Robertson+Stephen+P./26976146.html Tue, 25 Aug 2026 21:29:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26975986.html si-local-file:///var/storage/secattach/20260825/26975986.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26975986.html Tue, 25 Aug 2026 19:03:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26975986.html si-local-file:///var/storage/secattach/20260825/26975986.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26975986.html Tue, 25 Aug 2026 19:03:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+Robertson+Stephen+P./26962821.html si-local-file:///var/storage/secattach/20260821/26962821.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+Robertson+Stephen+P./26962821.html Fri, 21 Aug 2026 20:55:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+Robertson+Stephen+P./26962821.html si-local-file:///var/storage/secattach/20260821/26962821.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aurinia+Pharmaceuticals++++++++++++++++Filed+by%3A+Robertson+Stephen+P./26962821.html Fri, 21 Aug 2026 20:55:00 -0400 AUPH O.00888987 http://www.streetinsider.com/Upgrades/Bloom+Burton+%26+Co.+Upgrades+Aurinia+Pharmaceuticals+%28AUPH%29+to+Buy+%281%29/26953573.html <p>Bloom Burton & Co. analyst David Martin upgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) from Hold (3) to Buy (1) with a price target of $21.00.</p><p>For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals <a href="http://www.streetinsider.com/rating_history.php?q=AUPH">click here</a>. For more ratings news on Aurinia Pharmaceuticals <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AUPH&amp;type=analyst">click here</a>.</p><p>Shares of Aurinia Pharmaceuticals closed at $16.17 yesterday.</p> http://www.streetinsider.com/Upgrades/Bloom+Burton+%26+Co.+Upgrades+Aurinia+Pharmaceuticals+%28AUPH%29+to+Buy+%281%29/26953573.html Thu, 20 Aug 2026 08:38:57 -0400 AUPH http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26950176.html si-local-file:///var/storage/secattach/20260819/26950176.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26950176.html Wed, 19 Aug 2026 16:12:00 -0400 AUPH O.00888987 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26950176.html si-local-file:///var/storage/secattach/20260819/26950176.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aurinia+Pharmaceuticals+++For%3A+Aug+19/26950176.html Wed, 19 Aug 2026 16:12:00 -0400 AUPH O.00888987 http://www.streetinsider.com/Litigation/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html <p>Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has reached a settlement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation related to Teva's application to market a generic version of voclosporin 7.9 mg oral capsules in the United States.</p><p>Under the settlement terms, Teva acknowledged that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991, both expiring in December 2037, are valid, enforceable, and would be infringed by commercial sales of its generic voclosporin product in the United States. Teva agreed not to launch its generic product before December 7, 2036, unless certain defined contingencies occur. Any commercial launch will also require FDA approval.</p><p>Aurinia's patent http://www.streetinsider.com/Litigation/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html Wed, 19 Aug 2026 16:05:47 -0400 AUPH TEVA http://www.streetinsider.com/Litigation/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html <p>Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has reached a settlement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation related to Teva's application to market a generic version of voclosporin 7.9 mg oral capsules in the United States.</p><p>Under the settlement terms, Teva acknowledged that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991, both expiring in December 2037, are valid, enforceable, and would be infringed by commercial sales of its generic voclosporin product in the United States. Teva agreed not to launch its generic product before December 7, 2036, unless certain defined contingencies occur. Any commercial launch will also require FDA approval.</p><p>Aurinia's patent http://www.streetinsider.com/Litigation/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html Wed, 19 Aug 2026 16:05:47 -0400 AUPH TEVA http://www.streetinsider.com/Corporate+News/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html <p>Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has reached a settlement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation related to Teva's application to market a generic version of voclosporin 7.9 mg oral capsules in the United States.</p><p>Under the settlement terms, Teva acknowledged that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991, both expiring in December 2037, are valid, enforceable, and would be infringed by commercial sales of its generic voclosporin product in the United States. Teva agreed not to launch its generic product before December 7, 2036, unless certain defined contingencies occur. Any commercial launch will also require FDA approval.</p><p>Aurinia's patent http://www.streetinsider.com/Corporate+News/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html Wed, 19 Aug 2026 16:05:47 -0400 AUPH TEVA http://www.streetinsider.com/Corporate+News/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html <p>Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has reached a settlement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation related to Teva's application to market a generic version of voclosporin 7.9 mg oral capsules in the United States.</p><p>Under the settlement terms, Teva acknowledged that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991, both expiring in December 2037, are valid, enforceable, and would be infringed by commercial sales of its generic voclosporin product in the United States. Teva agreed not to launch its generic product before December 7, 2036, unless certain defined contingencies occur. Any commercial launch will also require FDA approval.</p><p>Aurinia's patent http://www.streetinsider.com/Corporate+News/Aurinia+settles+patent+dispute+with+Teva+over+generic+voclosporin/26950039.html Wed, 19 Aug 2026 16:05:47 -0400 AUPH TEVA http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659 http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html <p> EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation relating to Teva’s filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. </p><p> Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the ‎United States of http://www.streetinsider.com/Press+Releases/Aurinia+Settles+Patent+Litigation+with+Teva/26950014.html Wed, 19 Aug 2026 16:05:00 -0400 A.15795782 A.28362065 A.33218029 A.37314791 AUPH O.00003279 O.00172650 O.00888987 O.00982928 O.38359659